Delayed administration of recombinant plasma gelsolin improves survival in a murine model of severe influenza [version 1; peer review: 1 approved]

Zhiping Yang¹, Alice Bedugnis¹, Susan Levinson², Mark DiNubile², Thomas Stossel²+, Quan Lu¹, Lester Kobzik ²

¹Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA
²BioAegis Therapeutics, North Brunswick, NJ, 07960, USA
² Deceased author

Abstract

Background: Host-derived inflammatory responses contribute to the morbidity and mortality of severe influenza, suggesting that immunomodulatory therapy may improve outcomes. The normally circulating protein, human plasma gelsolin, is available in recombinant form (rhu-pGSN) and has beneficial effects in a variety of pre-clinical models of inflammation and injury.

Methods: We evaluated delayed therapy with subcutaneous rhu-pGSN initiated 3 to 6 days after intra-nasal viral challenge in a mouse model of influenza A/PR/8/34.

Results: Rhu-pGSN administered starting on day 3 or day 6 increased survival (12-day survival: 62 % vs 39 %, pGSN vs vehicle; p < 0.00001, summary of 18 trials), reduced morbidity, and decreased pro-inflammatory gene expression.

Conclusions: Rhu-pGSN improves outcomes in a highly lethal influenza model when given after a clinically relevant delay.

Keywords

influenza, pneumonia, plasma gelsolin, immunomodulation, host-directed
Corresponding author: Lester Kobzik (lkobzik@hsph.harvard.edu)

Author roles: Yang Z: Data Curation, Formal Analysis, Investigation, Methodology, Writing – Review & Editing; Bedugnis A: Investigation, Methodology, Project Administration; Levinson S: Conceptualization, Formal Analysis, Funding Acquisition, Project Administration, Writing – Review & Editing; DiNubile M: Conceptualization, Formal Analysis, Project Administration, Writing – Review & Editing; Stossel T: Conceptualization, Formal Analysis, Writing – Review & Editing; Lu Q: Funding Acquisition, Project Administration, Supervision, Writing – Review & Editing; Kobzik L: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Project Administration, Supervision, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: S. Levinson and M. DiNubile are employees and shareholders of BioAegis Therapeutics. T. Stossel is a founder, shareholder and consultant to BioAegis Therapeutics.

Grant information: This work was supported by the National Institutes of Health, grant number AI125152.

Copyright: © 2019 Yang Z et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Yang Z, Bedugnis A, Levinson S et al. Delayed administration of recombinant plasma gelsolin improves survival in a murine model of severe influenza [version 1; peer review: 1 approved] F1000Research 2019, 8:1860 (https://doi.org/10.12688/f1000research.21082.1)

First published: 06 Nov 2019, 8:1860 (https://doi.org/10.12688/f1000research.21082.1)
**Introduction**

Seasonal influenza continues to be a cause of substantial morbidity and mortality. There is also a fear that a new virulent influenza strain could cause high death rates, similar to those seen during the 1918 pandemic. The 2009 pandemic revealed the limitations of available public health interventions and current vaccines. While some antiviral drugs (e.g., oseltamivir) are currently in use, they suffer from a short time window of efficacy and increasing viral resistance. Hence, a substantial but unmet need exists for new therapeutic agents, especially for life-threatening infections.

The pathogenesis of influenza involves dysregulated and injurious host inflammatory responses. This observation suggests that better inflammation control with immunomodulatory therapy may be able to reduce the morbidity and mortality seen in severe infections. Recombinant human plasma gelsolin (rhu-pGSN) is an attractive candidate because it dampens excessive and injurious inflammation and augments antimicrobial defenses. Moreover, it has successfully passed several of the safety, toxicity, and regulatory tests needed to go from ‘bench to bedside’.

Gelsolin was first identified in the cytoplasm of macrophages. It was further identified in many vertebrate cells, and is a highly conserved protein with many functions. A unique characteristic of gelsolin at the gene level is the existence of a splice variant which encodes a distinct plasma isoform (pGSN). This isoform is released into extracellular fluids and differs from its cytoplasmic counterpart by the inclusion of an additional 25 amino acids at the N-terminal sequence. Normal mammalian blood contains pGSN at concentrations of 200–300 µg/ml, making it one of the most abundant proteins in plasma.

Among pGSN’s many functions is to dissolve the actin gels is the one that gave it its name: dissolving the actin gels that arise from cellular debris. The gels have the deleterious property of forming a protective biofilm that reduces the ability of cellular and humoral defenses to access embedded pathogenic organisms. This function leads to accumulation of pGSN at sites of tissue damage. The intereaction with actin reduces pGSN's binding to and inactivation of a host of microbial toxins and inflammatory mediators (for example, lyso phosphatic acid, sphingosine-1-phosphate, platelet-activating factor, fibronectin, endotoxin and lipoteichoic acid). The local dynamic balance of these mediators can modulate host defense. A final noteworthy function of pGSN is its ability to augment the phagocytosis and killing of both Gram-positive and -negative bacteria by macrophages. By stripping actin off macrophage scavenger receptors, pGSN promotes phagocytosis. It also enhances killing by stimulating the constitutive NOS3 enzyme system. As the acute injury subsides, pGSN is free to bind and inhibit inflammatory substances, promoting resolution of injury at the infectious site. The local capture of pGSN by exposed actin reduces the levels of pGSN in the circulation commensurate to the magnitude of tissue injury. The relative abundance of pGSN typically allows it to render inactive any pro-inflammatory mediators that enter the systemic circulation and helps to prevent organ damage distant from the injury site. In severe infection, systemic depletion of pGSN can result in loss of its protective effects. Indeed, there is a robust correlation between how much pGSN levels decrease and probability of mortality. As might be predicted from these observations, systemic treatment with pGSN has reduced pathologic changes and mortality in numerous preclinical animal disease models.

Relevant to the severe pneumonia seen in fatal influenza, administration of rhu-pGSN improved survival in murine primary or secondary (post-influenza) pneumococcal pneumonia, a benefit seen without any antibiotic treatment. These results have established proof-of-principle for the potential benefit of rhu-pGSN for bacterial pneumonias, including the secondary pneumonias often found as a complication of influenza. Here we report that rhu-pGSN improves outcomes in a mouse primary influenza model without superimposed bacterial infections.

**Methods**

All protocols were approved by the Harvard Medical Area Biosafety and Animal Care and Use Committees.

**Mouse model of influenza**

Normal 6- to 8-week-old male CD1 mice were obtained from Charles River Laboratories (Wilmington, MA). A murine-adapted strain of H1N1 influenza virus, A/Puerto Rico/8/1934 (PR8), quantified as plaque-forming units (PFU) was procured from ViraSource (Durham, NC). Mice were anesthetized with 72 mg/kg ketamine plus 9.6 mg/kg xylazine administered via intraperitoneal injection. Mice then received an intranasal instillation of 25 µl suspension of PBS containing virus (ranging from 400–1000 PFU depending on the trial) or vehicle alone. Initial titration identified 400 PFU as a dose that led to ~60% mortality in vehicle-treated mice, and this dose was used in a majority of the trials (see Table 1). Most trials used at least 10 mice per group for the vehicle and pGSN treatment groups; details of the influenza dose, total number of mice, and their weights are provided in the tables in Underlying Data.

**Treatments and outcomes**

Recombinant human pGSN (rhu-pGSN) was synthesized in E. coli and purified by Fujifilm Biosynth (Billingham, UK). Rhu-pGSN was administered daily to mice by subcutaneous injection starting on day 3 or 6 after infection, at doses ranging from 400–1000 PFU depending on the trial) or vehicle alone. Rhu-pGSN was administered daily to mice by subcutaneous injection starting on day 3 or 6 after infection, at doses ranging from 0.5–5 mg as detailed in the Results. We monitored the mice for 12 days, measuring survival, changes in weight and overall morbidity using a composite index (i.e., 1 point each for hunched appearance, ruffled fur or partly closed eyes; 1.5 points for prolapsed penis or splayed hind quarter; 2 points for listlessness, with a maximum score of 8; the assessment was performed without blinding to treatment group) adapted from guidelines described previously. Weights and mortality scores for the last day alive were carried forward for animals that did not survive.

**Lung transcriptome profiling**

Lung tissue was obtained on days 7 and 9 after infection from mice treated with either vehicle or rhu-pGSN (dosed 2 mg per day starting on day 3 after infection, then increased to 5 mg per day on day 7). RNA was isolated using the RNAEasy mini-kit (Qiagen, Germantown, MD) according to manufacturer’s
Table 1. Details of treatment trials using recombinant human plasma gelsolin (rhu-pGSN) in murine influenza.

<table>
<thead>
<tr>
<th>Trial #</th>
<th>Virus dose (PFU)</th>
<th>Treatment (start day)</th>
<th>pGSN dose (mg)</th>
<th>Treatment days</th>
<th>mice per group, n</th>
<th>Survival, %</th>
<th>Benefit*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>400</td>
<td>6</td>
<td>5</td>
<td>d6-11</td>
<td>10 10</td>
<td>10 60</td>
<td>YES</td>
</tr>
<tr>
<td>2</td>
<td>400</td>
<td>6</td>
<td>5</td>
<td>d6-11</td>
<td>10 9</td>
<td>10 44</td>
<td>NO</td>
</tr>
<tr>
<td>3</td>
<td>500</td>
<td>3</td>
<td>5</td>
<td>d3-11</td>
<td>10 10</td>
<td>10 50 20</td>
<td>NO</td>
</tr>
<tr>
<td>4</td>
<td>500</td>
<td>6</td>
<td>5</td>
<td>d6-11</td>
<td>10 10</td>
<td>10 44</td>
<td>NO</td>
</tr>
<tr>
<td>5</td>
<td>1000</td>
<td>6</td>
<td>5</td>
<td>d6-11</td>
<td>10 10</td>
<td>10 20 0</td>
<td>NO</td>
</tr>
<tr>
<td>6</td>
<td>400</td>
<td>6</td>
<td>5</td>
<td>d6-11</td>
<td>10 10</td>
<td>10 50 30</td>
<td>NO</td>
</tr>
<tr>
<td>7</td>
<td>600</td>
<td>6</td>
<td>5</td>
<td>d6-11</td>
<td>10 10</td>
<td>10 50 62</td>
<td>YES</td>
</tr>
<tr>
<td>8</td>
<td>400</td>
<td>6</td>
<td>5</td>
<td>d6-11</td>
<td>14 13</td>
<td>10 50 62</td>
<td>YES</td>
</tr>
<tr>
<td>9</td>
<td>400</td>
<td>6</td>
<td>8</td>
<td>d6-11</td>
<td>10 10</td>
<td>10 80 67</td>
<td>YES</td>
</tr>
<tr>
<td>10</td>
<td>400</td>
<td>6</td>
<td>8</td>
<td>d6-11</td>
<td>15 15</td>
<td>10 70 67</td>
<td>YES</td>
</tr>
<tr>
<td>11</td>
<td>400</td>
<td>3</td>
<td>5</td>
<td>d3-11</td>
<td>10 10</td>
<td>10 60 90</td>
<td>YES</td>
</tr>
<tr>
<td>12</td>
<td>400</td>
<td>3</td>
<td>8</td>
<td>d3-11</td>
<td>10 10</td>
<td>10 80 67</td>
<td>YES</td>
</tr>
<tr>
<td>13</td>
<td>400</td>
<td>6</td>
<td>8</td>
<td>d6-11</td>
<td>10 10</td>
<td>10 70 67</td>
<td>YES</td>
</tr>
<tr>
<td>14</td>
<td>500</td>
<td>3</td>
<td>5</td>
<td>d3-11</td>
<td>10 10</td>
<td>10 50 60</td>
<td>NO</td>
</tr>
<tr>
<td>15</td>
<td>500</td>
<td>3</td>
<td>5</td>
<td>d3-5</td>
<td>10 10</td>
<td>10 70 60</td>
<td>YES</td>
</tr>
<tr>
<td>16</td>
<td>400</td>
<td>6</td>
<td>5</td>
<td>d6-11</td>
<td>10 10</td>
<td>10 40 70</td>
<td>YES</td>
</tr>
<tr>
<td>17</td>
<td>400</td>
<td>3</td>
<td>5</td>
<td>d3-11</td>
<td>10 10</td>
<td>10 50 60</td>
<td>YES</td>
</tr>
<tr>
<td>18</td>
<td>400</td>
<td>3</td>
<td>5</td>
<td>d6-11</td>
<td>10 10</td>
<td>10 70 60</td>
<td>YES</td>
</tr>
</tbody>
</table>

* Treatment benefit scored as Yes if % survival ≥10% better with pGSN vs. Vehicle; No if % survival <10% better with pGSN.
instructions. RNA samples were analyzed using the Mouse DriverMap targeted gene expression profiling panel from Cellecta (Mountain View, CA). The Cellecta platform uses highly multiplexed RT-PCR amplification and next-generation sequencing (NGS) quantitation to measure expression of 4753 protein-coding and functionally significant mouse genes. The procedure detailed in the Cellecta User Manual, item 5.3 was followed to create amplified index libraries which were sequenced on an Illumina NextSeq 500 instrument. The sequencing data was converted to FASTQ format and then further analyzed using DriverMap Sample Extraction software. This produces a raw data matrix file of counts for each sample in columns aligned to the 4753 gene panel.

Statistical analysis
Data were analyzed using Prism (GraphPad Software) or SAS (SAS Institute) software. Differences in Kaplan-Meier survival curves were analyzed using a log-rank test with Sidak adjustment for multiple comparisons. A Breslow-Day test for homogeneity of the pGSN versus vehicle comparison across studies yielded p>0.2, indicating homogeneity could not be rejected and supporting the overall comparison across studies, which was carried out via the log-rank (Mantel-Cox) test stratified by trial. For other measurements, differences between groups were examined by ANOVA. The transcriptome profiling results scaled to normalize column counts, were converted to log2 counts (after addition of 0.1 to all cells to eliminate zero values) and then analyzed using Quilcore software (Lund, Sweden). Further analysis of gene set enrichment was performed using tools (Panther version 14.114 and MetaCore (version 19.3, Clarivate Analytics, Philadelphia, PA)) that allow evaluation using a custom background gene list (i.e., the ~4700 genes measured using the Cellecta DriverMap platform).

Results
Effect of rhu-pGSN on survival
We tested a variety of dose and timing regimens to evaluate the potential of rhu-pGSN to improve outcomes, conducting a total of 18 trials that are tabulated in Table 1 and summarized in Table 2. To mimic likely clinical usage, mice were not treated until several days post-challenge.

The main finding was that delayed treatment with rhu-pGSN resulted in significant improvement in the survival of mice (Figure 1). All studies combined yielded 39% (93/236) surviving mice treated with vehicle and 62% (241/389) surviving mice treated with pGSN on day 12 (p = 0.000001, Figure 1A). Improved survival was observed whether the delayed treatment was started on day 6 (Figure 1C) or day 3 after infection (Figures 1E, G). Similarly, compared to vehicle treatment, rhu-pGSN resulted in decreased morbidity scores (Figures 1B, D, F, H). In contrast, no statistically significant difference in weight loss or recovery (in surviving animals) was consistently observed in the experiments summarized in Figure 1. The sole exception was found in the trials testing a dose regimen of initially low (> 2 mg rhu-pGSN on days 3-6/7, then 5 mg through day 11). The latter set of trials led to weights (compared to day 0) at the end of study of 81.4 ± 4.7% in vehicle-treated mice versus 85 ± 2.6% in pGSN-treated mice (p < 0.0001, summary of 4 trials, see also Table 1 and Table 2, and more detailed tabulation of all experiments in Extended dataa). A beneficial effect of rhu-pGSN was observed in a majority but not all of the 18 individual trials (Table 1, see Discussion).

Transcriptome profiling
To evaluate whether rhu-pGSN treatment modified the transcriptome profile (see Underlying data) of infected lungs, we harvested lung tissue just before (day 7) and after (day 9) the usual onset of mortality (day 8) in this model (n = 5 per group per day). Comparison of lung samples obtained at day 7 showed no significant differences. In contrast, analysis of day 9 samples identified 344 differentially expressed genes in the rhu-pGSN-treated group, comprised of 195 down-regulated and 149 up-regulated genes. The top 50 up- and down-regulated genes are shown in Figure 2, which is notable for the many cytokine and immune-related genes prominent among those down-regulated in the rhu-pGSN-treated group (including IL10, IL12rb, CTLA4, and CCRs9, 7 and 5, among others). We performed gene

Table 2. Summary of survival data using different treatment regimens.

<table>
<thead>
<tr>
<th>Subset analyzed</th>
<th>Experiments analyzed, n</th>
<th>Viral dose, PFU(cohorts tested, n)</th>
<th>Vehicle start, n</th>
<th>Vehicle survived, n</th>
<th>Vehicle survival, %</th>
<th>pGSN start, n</th>
<th>pGSN survived, n</th>
<th>pGSN survival, %</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>All data</td>
<td>18</td>
<td>400 (21); 500 (11); 600 (1); 1000 (1)</td>
<td>236</td>
<td>93</td>
<td>39</td>
<td>389</td>
<td>241</td>
<td>62</td>
<td>&lt;0.000001</td>
</tr>
<tr>
<td>Treatment d6-11</td>
<td>11</td>
<td>400 (11); 500 (4); 600 (1)</td>
<td>148</td>
<td>59</td>
<td>40</td>
<td>172</td>
<td>110</td>
<td>64</td>
<td>0.000011</td>
</tr>
<tr>
<td>Treatment d3-11 2mg+</td>
<td>9</td>
<td>400 (7); 500 (7)</td>
<td>137</td>
<td>58</td>
<td>42</td>
<td>162</td>
<td>101</td>
<td>62</td>
<td>0.0005</td>
</tr>
<tr>
<td>Treatment start low 2 mg+ (d3-6/7) then high dose</td>
<td>4</td>
<td>400 (6)</td>
<td>67</td>
<td>34</td>
<td>51</td>
<td>71</td>
<td>55</td>
<td>77</td>
<td>0.0005</td>
</tr>
<tr>
<td>Treatment start very low (0.5-1) mg+ (d3-6/7) then high dose</td>
<td>3</td>
<td>400 (3)</td>
<td>35</td>
<td>19</td>
<td>54</td>
<td>43</td>
<td>24</td>
<td>56</td>
<td>0.62</td>
</tr>
</tbody>
</table>

pGSN, plasma gelsolin
Figure 1. Survival and morbidity analysis of different treatment regimens. Comparison of survival rates (A, C, E, G) and morbidity (B, D, F, H) in mice treated with rhu-pGSN or vehicle. (A, B) Results for all 18 trials (typically 10 or more mice per group, see details in Table 1 and Table 2) using delayed treatment. Some trials initiated treatment in different arms on day 6 or day 3. (C, D) Results for 13 trials using delayed treatment starting on day 6 or later. (E, F) Results for eight trials using treatment starting on day 3. (G, H) Results for four trials starting with an initially lower dose on day 3 with an increased dose starting on day 6/7. * = 0.000001, 0.00001, 0.0005, 0.0005 for A, C, E, G, respectively; p < 0.0001 for B, D, F, H.
enrichment analysis of the down-regulated gene list using the Panther online analysis tool to query GO Ontology or Reactome databases. The main findings were a reduction of expression of biological processes linked to immune and inflammatory responses, or release of cytokine and other cellular activators. The top 10 most significant processes/pathways are shown in Table 3. Analysis using a different gene enrichment analysis software tool (MetaCore) produced similar results. Analysis of the up-regulated gene list identified enrichment of processes related to tissue morphogenesis and epithelial/epidermal cell differentiation (consistent with repair of influenza-mediated damage, see Discussion). We present details of the DriverMap gene list, the differentially expressed genes identified, and the full results of gene enrichment analyses using the down- and up-regulated gene lists to query the Panther and MetaCore databases in worksheets 2–15 in a spreadsheet available in Extended data.

Discussion
We sought to evaluate the potential of rhu-pGSN to improve outcomes in severe influenza using a clinically relevant scenario of delaying initiation of treatment. The key finding was that delayed pGSN treatment significantly improved survival, either when used starting on day 3 or even starting as late as day 6 after infection.

Some limitations merit discussion. The first is the experimental variability we observed and report. Treatment with rhu-pGSN increased survival in a majority of the experiments conducted, but not in all of them. For a subset of the negative trials, we could
Table 3. Top 10 down-regulated Gene Ontology (GO) processes and pathways in plasma gelsolin (pGSN)-treated lung tissue (Day 9).

<table>
<thead>
<tr>
<th>GO biological process</th>
<th>Process genes in background list, n</th>
<th>Genes in day 9 downregulated genes in pGSN group, n</th>
<th>Expected genes, n</th>
<th>Fold enrichment</th>
<th>Raw P-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>immune system process (GO:0002376)</td>
<td>932</td>
<td>126</td>
<td>38.5</td>
<td>3.27</td>
<td>4.13E-40</td>
<td>5.59E-36</td>
</tr>
<tr>
<td>immune response (GO:0006955)</td>
<td>496</td>
<td>88</td>
<td>20.49</td>
<td>4.29</td>
<td>9.01E-33</td>
<td>6.09E-29</td>
</tr>
<tr>
<td>defense response (GO:0006952)</td>
<td>534</td>
<td>83</td>
<td>22.06</td>
<td>3.76</td>
<td>6.69E-27</td>
<td>3.02E-23</td>
</tr>
<tr>
<td>response to external biotic stimulus (GO:0043207)</td>
<td>500</td>
<td>78</td>
<td>20.66</td>
<td>3.78</td>
<td>4.19E-25</td>
<td>9.44E-22</td>
</tr>
<tr>
<td>response to biotic stimulus (GO:0009607)</td>
<td>511</td>
<td>79</td>
<td>21.11</td>
<td>3.74</td>
<td>3.03E-25</td>
<td>1.03E-21</td>
</tr>
<tr>
<td>response to other organism (GO:0051707)</td>
<td>500</td>
<td>78</td>
<td>20.66</td>
<td>3.78</td>
<td>4.19E-25</td>
<td>1.13E-21</td>
</tr>
<tr>
<td>regulation of immune system process (GO:0002682)</td>
<td>682</td>
<td>90</td>
<td>28.18</td>
<td>3.19</td>
<td>8.49E-25</td>
<td>1.64E-21</td>
</tr>
<tr>
<td>positive regulation of immune system process (GO:0002684)</td>
<td>485</td>
<td>75</td>
<td>20.04</td>
<td>3.74</td>
<td>8.83E-24</td>
<td>1.49E-20</td>
</tr>
<tr>
<td>response to external stimulus (GO:0009605)</td>
<td>928</td>
<td>100</td>
<td>38.34</td>
<td>2.61</td>
<td>8.64E-22</td>
<td>1.30E-18</td>
</tr>
<tr>
<td>defense response to other organism (GO:0098542)</td>
<td>343</td>
<td>61</td>
<td>14.17</td>
<td>4.3</td>
<td>1.14E-21</td>
<td>1.54E-18</td>
</tr>
</tbody>
</table>

**Reactome pathways**

<table>
<thead>
<tr>
<th>Pathway</th>
<th>Genes in background list, n</th>
<th>Genes in day 9 downregulated genes in pGSN group, n</th>
<th>Expected genes, n</th>
<th>Fold enrichment</th>
<th>Raw P-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune System (R-MMU-168256)</td>
<td>773</td>
<td>85</td>
<td>31.94</td>
<td>2.66</td>
<td>2.92E-18</td>
<td>4.52E-15</td>
</tr>
<tr>
<td>Cytokine Signaling in Immune system (R-MMU-1280215)</td>
<td>257</td>
<td>38</td>
<td>10.62</td>
<td>3.58</td>
<td>3.48E-11</td>
<td>2.69E-08</td>
</tr>
<tr>
<td>Adaptive Immune System (R-MMU-1280218)</td>
<td>299</td>
<td>37</td>
<td>12.35</td>
<td>3</td>
<td>6.13E-09</td>
<td>3.16E-06</td>
</tr>
<tr>
<td>Metabolism (R-MMU-1430728)</td>
<td>783</td>
<td>8</td>
<td>32.35</td>
<td>0.25</td>
<td>1.48E-07</td>
<td>5.72E-05</td>
</tr>
<tr>
<td>Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell (R-MMU-198933)</td>
<td>55</td>
<td>14</td>
<td>2.27</td>
<td>6.16</td>
<td>3.39E-07</td>
<td>1.05E-04</td>
</tr>
<tr>
<td>Innate Immune System (R-MMU-168249)</td>
<td>453</td>
<td>43</td>
<td>18.72</td>
<td>2.3</td>
<td>5.72E-07</td>
<td>1.48E-04</td>
</tr>
<tr>
<td>Signaling by Interleukins (R-MMU-449147)</td>
<td>192</td>
<td>24</td>
<td>7.93</td>
<td>3.03</td>
<td>3.33E-06</td>
<td>7.37E-04</td>
</tr>
<tr>
<td>GPVI-mediated activation cascade (R-MMU-114604)</td>
<td>26</td>
<td>9</td>
<td>1.07</td>
<td>8.38</td>
<td>5.84E-06</td>
<td>1.13E-03</td>
</tr>
<tr>
<td>DAP12 interactions (R-MMU-2172127)</td>
<td>20</td>
<td>7</td>
<td>0.83</td>
<td>8.47</td>
<td>6.27E-05</td>
<td>1.08E-02</td>
</tr>
<tr>
<td>Interleukin-2 family signaling (R-MMU-451927)</td>
<td>30</td>
<td>8</td>
<td>1.24</td>
<td>6.45</td>
<td>9.32E-05</td>
<td>1.31E-02</td>
</tr>
</tbody>
</table>

Postulate plausible potential explanations (e.g., technical issues with the viral stock, variation in instillation method, insufficient initial rhu-pGSN dose in the ‘low dose then high dose’ trials). To the extent possible, we adjusted our methods to reduce these potential sources of variability. However, for the remainder of the negative trials we simply do not have a good explanation for the outcome. Hence, we have chosen to present all the data whether positive or negative to provide a full report of the findings.

We also manipulated the experimental variables, in part to address larger questions (e.g., can treatment as late as day 6 vs day 3 after onset of infection be effective?) and in some cases to explore potential reasons for the intermittent variability in our results (e.g., trial 14 tested the potential influence of differences in initial weight of the mice we used). Ultimately, we observed beneficial effects whether the survival analysis included all the trials (Figures 1A, B) or those using treatment starting at day 6 or day 3 (Figures 1C–H).

Notably, rhu-pGSN did not rescue all of the mice dying from influenza in our model, offering only a partial (albeit significant) survival benefit. Given the goal of identifying a novel therapy for severe influenza, an optimistic interpretation is that this occurred in mice without the supportive fluid and respiratory care given to hospitalized patients, and that similar or more robust benefits might be observed in the clinical setting. The results establish a potential benefit for rhu-pGSN but this potential needs further evaluation in a larger animal model, e.g. ferret and then (if results warrant), testing in a clinical trial to determine its role in therapy for severe influenza in human patients. Our findings rely on studies with only one strain of influenza in only one strain of one model species, the mouse. Nevertheless, we favor future experimentation in a larger animal model as the logical next step, rather than further studies in mice. Additional investigations using other influenza or mouse strains would not resolve the suggestion (hope) of possible clinical benefit offered by our results. Hence, large animal experiments deserve priority.
Our study did not address the mechanism(s) for the beneficial action of rhu-pGSN. The available literature identifies numerous inflammatory mediators whose function can be modulated by pGSN (e.g. sphingosine-1-phosphate, endotoxin, platelet activating factor). The transcriptome profiling results are consistent with a beneficial down-regulation of the overly exuberant immune and inflammatory response that characterizes severe influenza. Further investigation of the many possible single or combination targets by which pGSN may be acting is warranted. However, a complete delineation of its mechanisms will take substantial effort and time to achieve. If effective, therapeutic use of rhu-pGSN should be pursued even in the absence of a full map of its complex effects. This position reflects in part the fact that pGSN is a normal, abundant protein in human plasma, and has passed initial safety evaluation in human subjects with community acquired pneumonia (personal communication, Levinson, S. & DiNubile, M.). Finally, it is worth speculating that rhu-pGSN treatment may also benefit patients with severe influenza by reducing the risk of the common complication of secondary bacterial pneumonia. This possibility is suggested by other studies from our laboratory, showing rhu-pGSN improved survival of mice with post-influenza bacterial pneumonia.

In summary, rhu-pGSN can improve outcomes in a highly lethal murine influenza model when given after a clinically relevant delay. These findings are consistent with the benefits seen in models of pneumococcal pneumonia. The modes of action for pGSN involve host responses and do not seem to depend on the absence of a full map of its complex effects. This position will take substantial effort and time to achieve. If effective, therapeutic use of pGSN should be pursued even in the absence of a full map of its complex effects. This position reflects in part the fact that pGSN is a normal, abundant protein in human plasma, and has passed initial safety evaluation in human subjects with community acquired pneumonia (personal communication, Levinson, S. & DiNubile, M.). Finally, it is worth speculating that rhu-pGSN treatment may also benefit patients with severe influenza by reducing the risk of the common complication of secondary bacterial pneumonia. This possibility is suggested by other studies from our laboratory, showing rhu-pGSN improved survival of mice with post-influenza bacterial pneumonia.

## Data availability

**Underlying data**

Harvard Dataverse: Expanded Tables 1 & 2. [https://doi.org/10.7910/DVN/53GIY](https://doi.org/10.7910/DVN/53GIY)

This project contains data on each experimental group, as shown in Table 1 and Table 2, with additional variables, such as weight, and statistical analyses.


**Extended data**

Harvard Dataverse: Transcriptome analysis of gelsolin vs vehicle treatment in mouse influenza infected lungs. [https://doi.org/10.7910/DVN/8HBFD7](https://doi.org/10.7910/DVN/8HBFD7)

**Reporting guidelines**

Harvard Dataverse: ARRIVE checklist for ‘Delayed administration of recombinant plasma gelsolin improves survival in a murine model of severe influenza’. [https://doi.org/10.7910/DVN/VQBLFP](https://doi.org/10.7910/DVN/VQBLFP)

Data hosted on Harvard Dataverse are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).

## Acknowledgements

The authors thank Dr. James Bolognesi for consultation on statistical analysis.

## References


Open Peer Review

Current Peer Review Status: 

Version 1

Reviewer Report 18 November 2019

https://doi.org/10.5256/f1000research.23201.r56255

© 2019 Dockrell D. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

David H. Dockrell
MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK

Yang et al. explore the potential for recombinant human gelsolin as a therapeutic intervention in a PR8 H1N1 mouse flu model. They use CD1 mice and use a variety of doses and dosing schedules with a pooled statistical analysis to infer benefits across a range of groups despite some variability in results. Benefits were seen in terms of survival and morbidity scores but not in terms of weight loss. They went on to perform transcriptional profiling and to detect reductions in inflammatory responses and increases in responses associated with tissue repair.

Strengths of the study are the investigation of a therapeutic approach for a potential life threatening infection and the preliminary hypothesis generating transcriptomic data set which provide clues to potential mechanisms. A few areas of the text should be addressed to strengthen the main conclusions.

The authors have had significant statistical input but some further explanation of the statistical approach and its potential benefits to a study such as this would be useful.

The study used CD1 mice which may explain some of the variability. A few further details should be added to the methods. The authors should confirm the reason for just studying males. They should confirm animals and groups were co-housed and, in a study with such large numbers, explain whether there were any major groupings or time periods used in the study which might have contributed to variability. Were mice bought in in small groups or are the subgroups from predominantly the same larger pool bred in house? Also they should confirm the mice were infected at similar times of day.

The authors might also comment on the rationale for using human gelsolin. Some differences in response between human and mouse gelsolin have been detected and the authors might wish to comment on this and their similarities and differences.

The authors did not find any major differences in weight. Can the authors comment further on this since this is usually a marker of outcome. In addition the mortality curves appeared to be still showing deaths at the end of the study period. Can the authors confirm that the main biologic affect was a delay in mortality rather than prevention? Clarifying this in the text would resolve any uncertainty relating to the conclusion.
The transcriptomic data is of interest. Can the authors drill down further and confirm any sub-groupings related to inflammation or tissue repair? In particular is their any evidence of an epithelial protective affect such as enhancement of barrier function or epithelial apoptosis inhibition, since this is potentially one of gelsolins biologic functions. I assume there is no additional data from BAL cytokines, cell counts or histology to back up the transcriptomics but if there are any further data, they would strengthen the conclusions.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Partly

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Pathogeneiss of infectious diseases, especially respiratory tract infections.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com